image
Healthcare - Biotechnology - NASDAQ - US
$ 0.2351
-6.96 %
$ 292 K
Market Cap
None
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VRPX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.235 USD, Virpax Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VRPX stock under the base case scenario is HIDDEN Compared to the current market price of 0.235 USD, Virpax Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one VRPX stock under the best case scenario is HIDDEN Compared to the current market price of 0.235 USD, Virpax Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VRPX

image
$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.0$2.0$2.0$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-12.1 B OPERATING INCOME
-76892.34%
-12.1 B NET INCOME
-79344.48%
-16.7 B OPERATING CASH FLOW
-169509.16%
0 INVESTING CASH FLOW
0.00%
9.08 B FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-3.39 M OPERATING INCOME
-76.41%
-3.39 M NET INCOME
-68.96%
-2.87 M OPERATING CASH FLOW
35.77%
0 INVESTING CASH FLOW
0.00%
4.37 M FINANCING CASH FLOW
66.93%
Balance Sheet Virpax Pharmaceuticals, Inc.
image
Current Assets 1.56 B
Cash & Short-Term Investments 1.51 B
Receivables 0
Other Current Assets 42.6 M
Non-Current Assets 0
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 0
97.26 %Total Assets$1.6b
Current Liabilities 2.47 B
Accounts Payable 0
Short-Term Debt 0
Other Current Liabilities 2.47 B
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
100.00 %Total Liabilities$2.5b
EFFICIENCY
Earnings Waterfall Virpax Pharmaceuticals, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 12.1 B
Operating Income -12.1 B
Other Expenses -12.7 M
Net Income -12.1 B
00(2b)(2b)(4b)(4b)(6b)(6b)(8b)(8b)(10b)(10b)(12b)(12b)(14b)(14b)000(12b)(12b)13m(12b)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
1320.61% ROE
1320.61%
-775.72% ROA
-775.72%
1322.00% ROIC
1322.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Virpax Pharmaceuticals, Inc.
image
00(2b)(2b)(4b)(4b)(6b)(6b)(8b)(8b)(10b)(10b)(12b)(12b)(14b)(14b)(16b)(16b)(18b)(18b)20192019202020202021202120222022202320232024202420252025
Net Income -12.1 B
Depreciation & Amortization 91 M
Capital Expenditures 0
Stock-Based Compensation 135 M
Change in Working Capital -4.78 M
Others -4.78 B
Free Cash Flow -16.7 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Virpax Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for VRPX of $3 , with forecasts ranging from a low of $3 to a high of $3 .
VRPX Lowest Price Target Wall Street Target
3 USD 1176.05%
VRPX Average Price Target Wall Street Target
3 USD 1176.05%
VRPX Highest Price Target Wall Street Target
3 USD 1176.05%
Price
Max Price Target
Min Price Target
Average Price Target
8080707060605050404030302020101000Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Virpax Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Virpax Pharmaceuticals Announces Reverse Stock Split BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on. businesswire.com - 1 month ago
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND BERWYN, Penn.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding (“DRF”) study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediat. businesswire.com - 1 month ago
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look t. businesswire.com - 1 month ago
Virpax's NES100 to be Presented at The Society of Toxicology by NCATS BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its NES100 dose range finding toxicity study will be presented at The Society of Toxicology (SOT) 64th annual meeting and Tox Expo taking place March 16-20th in Orlando, FL. This is a p. businesswire.com - 1 month ago
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate On Friday, Virpax Pharmaceuticals, Inc.  VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA). benzinga.com - 2 months ago
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its senior director of portfolio management, Matthew Barnes, will be presenting at Outsourcing in Clinical Trial Conference. The Outsourcing in Clinical Trials (OCT) is a leading confer. businesswire.com - 3 months ago
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement agent for Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) in the successful close of its $6 million follow-on offering. globenewswire.com - 3 months ago
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $6.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.20 per share (minus $0.00001 per pr. businesswire.com - 3 months ago
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™ BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding (“DRF”) study for Probudur. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate. businesswire.com - 5 months ago
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the c. businesswire.com - 5 months ago
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s (Nasdaq: VRPX) successful $5.0 million public offering of common stock and pre-funded warrants. globenewswire.com - 5 months ago
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per pr. businesswire.com - 5 months ago
8. Profile Summary

Virpax Pharmaceuticals, Inc. VRPX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 292 K
Dividend Yield 0.00%
Description Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Contact 1055 Westlakes Drive, Berwyn, PA, 19312 https://www.virpaxpharma.com
IPO Date Feb. 17, 2021
Employees 2
Officers Mr. Jatinder Dhaliwal Chief Executive Officer & Chairman Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. Chief Scientific Officer